Stockscreener 앱 받기
16.21
1.33%
0.2196
Eyepoint Inc 주식(EYPT)의 최신 뉴스
Certain Pre-Funded Warrants of EyePoint, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
Certain Stock Options of EyePoint, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
68,889,649 Common Stock of EyePoint, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
Cormorant Asset Management Reduces Stake in EyePoint Pharmaceuti - GuruFocus
After Leaping 38% EyePoint, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar - simplywall.st
Update Report: Is EyePoint Pharmaceuticals Inc stock positioned for long term growth2025 Biggest Moves & High Accuracy Swing Trade Signals - moha.gov.vn
Stempoint Capital LP Acquires New Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint stock maintains Outperform rating at Mizuho amid competitor moves By Investing.com - Investing.com Australia
EyePoint stock maintains Outperform rating at Mizuho amid competitor moves - Investing.com
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Walleye Capital LLC Has $1.88 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint (EYPT) Is Up 25.0% After DURAVYU Phase 3 Safety Green Light And $200M ATM Offering - simplywall.st
Federated Hermes Inc. Has $43.28 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Understanding Momentum Shifts in (EYPT) - news.stocktradersdaily.com
EyePoint Pharmaceuticals changes name to EyePoint Inc - marketscreener.com
EyePoint Pharmaceuticals changes name to EyePoint, Inc., retains EYPT ticker - Investing.com
EyePoint Pharmaceuticals Announces Official Name Change - TipRanks
EyePoint Pharmaceuticals changes name to EyePoint, Inc., retains EYPT ticker By Investing.com - Investing.com India
EyePoint Pharmaceuticals announces official name change - MSN
EyePoint Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Sets New 12-Month HighHere's What Happened - MarketBeat
How EyePoint Pharmaceuticals Inc. (PV3B) stock responds to job market shiftsMarket Growth Review & Community Consensus Trade Signals - Newser
Can EyePoint Pharmaceuticals Inc. (PV3B) stock deliver strong annual returnsWeekly Trading Summary & Real-Time Volume Trigger Notifications - Newser
How buyback programs support EyePoint Pharmaceuticals Inc. (PV3B) stockMarket Risk Report & Smart Investment Allocation Tips - Newser
Will EyePoint Pharmaceuticals Inc. stock outperform value stocksQuarterly Portfolio Review & AI Powered Trade Plan Recommendations - Newser
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD - Investing.com
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD By Investing.com - Investing.com South Africa
Will EyePoint Pharmaceuticals Inc. (PV3B) stock outperform energy sector in 2025CPI Data & Weekly Return Optimization Plans - Newser
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Is EyePoint Pharmaceuticals Inc. (PV3B) stock positioned for secular growthWeekly Earnings Recap & Fast Entry Momentum Alerts - Newser
EyePoint Pharmaceuticals: Promising Outlook for Duravyu in Wet AMD Treatment and Strategic Growth Potential - TipRanks
EyePoint Pharmaceuticals Director Sells Shares - TradingView
XTX Topco Ltd Acquires 94,210 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
What drives EyePoint Pharmaceuticals Inc stock priceEvening Star Patterns & Exceptional Return Capital - earlytimes.in
Investors Appear Satisfied With EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Prospects As Shares Rocket 26% - 富途牛牛
EyePoint Pharmaceuticals (EYPT) Is Up 8.4% After Positive Phase 3 Safety Review for DURAVYU - Sahm
Officer/Dir Lurker Files To Sell 500 Of EyePoint Pharmaceuticals Inc [EYPT] - TradingView
What analysts say about EyePoint Pharmaceuticals Inc PV3B stockHigh Dividend Yield Stocks & Access Free Risk Analysis Before You Invest - earlytimes.in
Avoiding Lag: Real-Time Signals in (EYPT) Movement - news.stocktradersdaily.com
EyePoint Pharmaceuticals (EYPT): A Fresh Valuation Look Following Key DURAVYU Phase 3 Safety Review Completion - Sahm
Will EyePoint Pharmaceuticals Inc. stock see PE expansionJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - BỘ NỘI VỤ
Franklin Resources Inc. Buys 151,262 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 By Investing.com - Investing.com Nigeria
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 - Investing.com
EyePoint receives second consecutive positive recommendation from DSMC - Modern Retina
Why Institutions Believe Infibeam Avenues Limited Is Undervalued TodayStock Watchlist Updates & Collaborate and Win Together - earlytimes.in
EyePoint Pharmaceuticals (EYPT) Clears Phase 3 Safety Hurdle for DURAVYU—Is a New Wet AMD Era Ahead? - Sahm
Can EyePoint Pharmaceuticals Inc. (PV3B) stock sustain double digit ROETrade Risk Report & Detailed Earnings Play Alerts - newser.com
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Australia
0.56%
1.23%
자본화:
|
볼륨(24시간):